NO3068699T3 - - Google Patents
Info
- Publication number
- NO3068699T3 NO3068699T3 NO14798816A NO14798816A NO3068699T3 NO 3068699 T3 NO3068699 T3 NO 3068699T3 NO 14798816 A NO14798816 A NO 14798816A NO 14798816 A NO14798816 A NO 14798816A NO 3068699 T3 NO3068699 T3 NO 3068699T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799177P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3068699T3 true NO3068699T3 (https=) | 2018-03-31 |
Family
ID=50382477
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14798188A NO2997033T3 (https=) | 2013-03-15 | 2014-04-18 | |
| NO14798816A NO3068699T3 (https=) | 2013-03-15 | 2014-11-12 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14798188A NO2997033T3 (https=) | 2013-03-15 | 2014-04-18 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9700558B2 (https=) |
| EP (2) | EP2968313B1 (https=) |
| JP (1) | JP6560986B2 (https=) |
| KR (1) | KR102177982B1 (https=) |
| CN (1) | CN105142638B (https=) |
| AU (1) | AU2014229739B2 (https=) |
| CA (2) | CA2902403C (https=) |
| CY (2) | CY1120020T1 (https=) |
| DK (2) | DK2968312T3 (https=) |
| ES (2) | ES2660317T3 (https=) |
| HR (1) | HRP20180684T1 (https=) |
| HU (2) | HUE038899T2 (https=) |
| IL (1) | IL240846A0 (https=) |
| LT (1) | LT2968313T (https=) |
| MX (1) | MX374412B (https=) |
| NO (2) | NO2997033T3 (https=) |
| PL (2) | PL2968313T3 (https=) |
| PT (2) | PT2968312T (https=) |
| RS (1) | RS57075B1 (https=) |
| RU (1) | RU2666624C2 (https=) |
| SI (2) | SI2968312T1 (https=) |
| SM (1) | SMT201800134T1 (https=) |
| TR (1) | TR201802725T4 (https=) |
| WO (2) | WO2014140648A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968313B1 (en) | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| DK3142701T3 (en) | 2014-05-12 | 2018-08-13 | Verona Pharma Plc | New treatment |
| US20170119744A1 (en) * | 2014-06-18 | 2017-05-04 | Cipla Limited | Pharmaceutical Composition Comprising a Beta-2-Agonist and Anticholinergic Agent |
| CN110051627A (zh) | 2014-09-15 | 2019-07-26 | 维罗纳制药公司 | 包含rpl554的液体吸入制剂 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| US9827288B2 (en) * | 2015-09-21 | 2017-11-28 | Mycomagic Biotechnology Co., Ltd. | Method for treating a refractory or relapsed lung cancer |
| GB201613054D0 (en) | 2016-07-28 | 2016-09-14 | Verona Pharma Plc | New compound and process |
| GB2578093B (en) * | 2018-10-09 | 2020-11-18 | Verona Pharma Plc | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| WO2020077333A1 (en) | 2018-10-12 | 2020-04-16 | Ppg Industries Ohio, Inc. | Compositions containing thermally conductive fillers |
| WO2020150460A1 (en) * | 2019-01-18 | 2020-07-23 | Milne Iii Donald A | Micronized aspirin formulation |
| GB201911517D0 (en) | 2019-08-12 | 2019-09-25 | Verona Pharma Plc | Pharmaceutical composition |
| AU2021208129A1 (en) * | 2020-01-15 | 2022-08-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical composition of tricyclic PDE3/PDE4 dual inhibitor compound |
| GB202002786D0 (en) | 2020-02-27 | 2020-04-15 | Verona Pharma Plc | Liquid pharmaceutical composition |
| CN113975237B (zh) * | 2020-07-27 | 2024-12-20 | 盈科瑞（天津）创新医药研究有限公司 | 阿地溴铵吸入型冻干剂及其制备方法 |
| CN116917287A (zh) | 2021-04-29 | 2023-10-20 | 苏州盛迪亚生物医药有限公司 | 异喹啉酮类化合物及其用途 |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| WO2024033625A1 (en) * | 2022-08-08 | 2024-02-15 | Verona Pharma Plc | Ensifentrine (rpl-554) for increasing trough lung function |
| CN120787157A (zh) * | 2022-10-20 | 2025-10-14 | 维罗纳制药公司 | 使用恩塞芬汀治疗特发性肺纤维化 |
| CN120897742A (zh) * | 2022-11-15 | 2025-11-04 | 福睿德姆生物科学公司 | 通过抑制9型磷酸二酯酶增强血清素能致幻药物在治疗或预防某些神经精神障碍中的功效 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| CN121620356A (zh) | 2023-06-26 | 2026-03-06 | 维罗纳制药公司 | 包含恩塞芬汀的颗粒组合物 |
| US20250073240A1 (en) * | 2023-09-06 | 2025-03-06 | Verona Pharma Plc | New treatment |
| WO2025093848A1 (en) * | 2023-11-01 | 2025-05-08 | Verona Pharma Plc | Ensifentrine for treating bronchiectasis |
| CN117457114B (zh) * | 2023-12-25 | 2024-03-12 | 大连锦辉盛世科技有限公司 | 一种西药药学成分数据智能存储管理方法 |
| US20250249007A1 (en) * | 2024-02-07 | 2025-08-07 | Verona Pharma Plc | Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| WO1992022286A1 (en) | 1991-06-12 | 1992-12-23 | Minnesota Mining And Manufacturing Company | Albuterol sulfate suspension aerosol formulations |
| EP0617610B1 (en) | 1991-12-18 | 1997-03-19 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| DE19626373A1 (de) * | 1996-07-02 | 1998-01-08 | Boehringer Ingelheim Kg | Neuartige Verwendung von Wirkstoffen, welche die Funktion von nichtneuronalem Acetylcholin beeinflussen |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| ID27887A (id) | 1998-04-18 | 2001-05-03 | Glaxo Group Ltd | Formulasi aerosol farmasi |
| GB9808802D0 (en) | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
| SE9804000D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New composition of matter |
| ES2208310T3 (es) | 1999-03-31 | 2004-06-16 | Vernalis Limited | Derivados de pirimido(6,1-a) isoquinolin-4-ona. |
| PT1169019E (pt) | 1999-04-14 | 2003-07-31 | Glaxo Group Ltd | Formulacao farmaceutica em aerossol |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| EP1366025B1 (en) | 2001-03-08 | 2007-06-27 | Glaxo Group Limited | Agonists of beta-adrenoreceptors |
| JP4143413B2 (ja) | 2001-03-22 | 2008-09-03 | グラクソ グループ リミテッド | β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体 |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| WO2005074982A2 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| ATE474601T1 (de) * | 2004-05-31 | 2010-08-15 | Almirall Sa | Kombinationen mit antimuskarin-wirkstoffen und pde4-hemmern |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| CN1843453A (zh) * | 2005-04-06 | 2006-10-11 | 上海绿谷（集团）有限公司 | 一种治疗不孕症的中药组合物及其制备方法 |
| WO2007045980A1 (en) | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type iv inhibitors |
| EP2111861A1 (en) * | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
| WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
| GB0919742D0 (en) * | 2009-11-11 | 2009-12-30 | Millipore Corp | Optical sensor |
| PH12013500261A1 (en) * | 2010-08-09 | 2013-03-04 | Verona Pharma Plc | Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound |
| EP2968313B1 (en) | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
-
2014
- 2014-03-17 EP EP14712717.9A patent/EP2968313B1/en active Active
- 2014-03-17 DK DK14712716.1T patent/DK2968312T3/en active
- 2014-03-17 RS RS20180229A patent/RS57075B1/sr unknown
- 2014-03-17 ES ES14712717.9T patent/ES2660317T3/es active Active
- 2014-03-17 CA CA2902403A patent/CA2902403C/en active Active
- 2014-03-17 MX MX2015011778A patent/MX374412B/es active IP Right Grant
- 2014-03-17 JP JP2015562338A patent/JP6560986B2/ja active Active
- 2014-03-17 HU HUE14712716A patent/HUE038899T2/hu unknown
- 2014-03-17 SI SI201430689T patent/SI2968312T1/en unknown
- 2014-03-17 SM SM20180134T patent/SMT201800134T1/it unknown
- 2014-03-17 RU RU2015144083A patent/RU2666624C2/ru active
- 2014-03-17 TR TR2018/02725T patent/TR201802725T4/tr unknown
- 2014-03-17 WO PCT/GB2014/050834 patent/WO2014140648A1/en not_active Ceased
- 2014-03-17 DK DK14712717.9T patent/DK2968313T3/en active
- 2014-03-17 KR KR1020157028970A patent/KR102177982B1/ko active Active
- 2014-03-17 PL PL14712717T patent/PL2968313T3/pl unknown
- 2014-03-17 CN CN201480015150.8A patent/CN105142638B/zh active Active
- 2014-03-17 LT LTEP14712717.9T patent/LT2968313T/lt unknown
- 2014-03-17 CA CA2902400A patent/CA2902400C/en active Active
- 2014-03-17 PL PL14712716T patent/PL2968312T3/pl unknown
- 2014-03-17 EP EP14712716.1A patent/EP2968312B1/en active Active
- 2014-03-17 US US14/771,109 patent/US9700558B2/en active Active
- 2014-03-17 US US14/771,097 patent/US9717732B2/en active Active
- 2014-03-17 ES ES14712716.1T patent/ES2666098T3/es active Active
- 2014-03-17 PT PT147127161T patent/PT2968312T/pt unknown
- 2014-03-17 WO PCT/GB2014/050833 patent/WO2014140647A1/en not_active Ceased
- 2014-03-17 PT PT147127179T patent/PT2968313T/pt unknown
- 2014-03-17 AU AU2014229739A patent/AU2014229739B2/en active Active
- 2014-03-17 HU HUE14712717A patent/HUE037275T2/hu unknown
- 2014-03-17 HR HRP20180684TT patent/HRP20180684T1/hr unknown
- 2014-03-17 SI SI201430643T patent/SI2968313T1/en unknown
- 2014-04-18 NO NO14798188A patent/NO2997033T3/no unknown
- 2014-11-12 NO NO14798816A patent/NO3068699T3/no unknown
-
2015
- 2015-08-26 IL IL240846A patent/IL240846A0/en unknown
-
2017
- 2017-06-05 US US15/614,440 patent/US10471063B2/en active Active
-
2018
- 2018-03-12 CY CY20181100299T patent/CY1120020T1/el unknown
- 2018-04-26 CY CY20181100438T patent/CY1120346T1/el unknown